Gland Pharma Ltd receives EIR from US FDA for JNPC Facility, Visakhapatnam

Gland Pharma Limited has announced that following the Pre-approval inspection (PAI) for Sterile APIs at the Company's Facility at JNPC, Visakhapatnam between February 19, 2025, and February 25, 2025; the Company has received Establishment Inspection Report (EIR) from the US FDA indicating closure of the inspection.

Shares of Gland Pharma Limited was last trading in BSE at Rs. 1743.80 as compared to the previous close of Rs. 1721.65. The total number of shares traded during the day was 2161 in over 313 trades.

The stock hit an intraday high of Rs. 1749.00 and intraday low of 1705.00. The net turnover during the day was Rs. 3735477.00.

Source : Equity Bulls

Keywords

GlandPharma INE068V01023 USFDA PreApprovalInspection SterileAPIs JNPC Visakhapatnam EIR